Abstract

During labor, monocytes infiltrate massively the myometrium and differentiate into macrophages secreting high levels of reactive oxygen species and of pro-inflammatory cytokines (i.e. IL-1β), leading to myometrial contraction. Although IL-1β is clearly implicated in labor, its function and that of the inflammasome complex that cleaves the cytokine in its active form, has never been studied on steps preceding contraction. In this work, we used our model of lipopolysaccharide-induced preterm labor to highlight their role. We demonstrated that IL-1β was secreted by the human myometrium during labor or in presence of infection and was essential for myometrial efficient contractions as its blockage with an IL-1 receptor antagonist (Anakinra) or a neutralizing antibody completely inhibited the induced contractions. We evaluated the implication of the inflammasome on myometrial contractions and differentiation stages of labor onset. We showed that the effects of macrophage-released IL-1β in myometrial cell transactivation were blocked by inhibition of the inflammasome, suggesting that the inflammasome by producing IL-1β was essential in macrophage/myocyte crosstalk during labor. These findings provide novel innovative approaches in the management of preterm labor, specifically the use of an inflammasome inhibitor to block the precursor stages of labor before the acquisition of the contractile phenotype.

Details

Title
A pivotal role for the IL-1β and the inflammasome in preterm labor
Author
Lopez, T. E. 1 ; Zhang, H. 2 ; Bouysse, E. 1 ; Neiers, F. 3 ; Ye, X. Y. 4 ; Garrido, C. 5 ; Wendremaire, M. 1 ; Lirussi, Frédéric 6 

 INSERM U1231, Labex LIPSTIC and Label of Excellence from la Ligue Nationale Contre le Cancer, Dijon, France (GRID:grid.508062.9); University of Burgundy, Faculty of Medicine and Pharmacy, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313) 
 INSERM U1231, Labex LIPSTIC and Label of Excellence from la Ligue Nationale Contre le Cancer, Dijon, France (GRID:grid.508062.9); Hangzhou Normal University, School of Pharmacy, Hangzhou, China (GRID:grid.410595.c) (ISNI:0000 0001 2230 9154) 
 University of Burgundy, Faculty of Medicine and Pharmacy, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313) 
 Hangzhou Normal University, School of Pharmacy, Hangzhou, China (GRID:grid.410595.c) (ISNI:0000 0001 2230 9154) 
 INSERM U1231, Labex LIPSTIC and Label of Excellence from la Ligue Nationale Contre le Cancer, Dijon, France (GRID:grid.508062.9); University of Burgundy, Faculty of Medicine and Pharmacy, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); Cancer Center George-François Leclerc, Dijon, France (GRID:grid.5613.1) 
 INSERM U1231, Labex LIPSTIC and Label of Excellence from la Ligue Nationale Contre le Cancer, Dijon, France (GRID:grid.508062.9); University Hospital Besançon, Laboratory of Pharmacology-Toxicology, Platform PACE, Besançon, France (GRID:grid.411158.8) (ISNI:0000 0004 0638 9213); University of Franche-Comté, Faculty of Medicine and Pharmacy, Besançon, France (GRID:grid.7459.f) (ISNI:0000 0001 2188 3779) 
Pages
4234
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2928723695
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.